A phase II study of the potent PARP inhibitor, rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation.
Plummer, R Steven, N Scott, L Middleton, M Wilson, R Mulligan, E Curtin, N Wang, D Dewji, R
Plummer, R
Steven, N
Scott, L
Middleton, M
Wilson, R
Mulligan, E
Curtin, N
Wang, D
Dewji, R
Citations
Altmetric:
Abstract
poly(ADP ribose) polymerase inhibition has been shown to potentiate the cytotoxicity of DNA damaging agents. A phase I study of rucaparib and temozolomide showed that full-dose temozolomide could be given during PARP inhibition. We report the results of a phase II study of intravenous rucaparib 12 mg/m(2) and oral temozolomide 200 mg/m(2) on days 1-5 every 28 days in patients with advanced metastatic melanoma.
Description
Date
2013-05
Publisher
Collections
Keywords
Type
Article
Citation
A phase II study of the potent PARP inhibitor, rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation. 2013, 71 (5):1191-9 Cancer Chemother Pharmacol